More about Bayer CropScience Limited
Fundamentals for Bayer CropScience Limited
Regulatory Filings for Bayer CropScience Limited
Why Oman Is Now India's Most Strategic Trade Partner
Infrastructure Bet Fuels Cement Surge
Apollo FY26: When Healthcare Becomes a Flywheel
NITI Blueprint Could Turn Brain Drain Into $135Bn Engine
Fundamentals for Bayer CropScience Limited
Business Operations:
Sector: Basic MaterialsIndustry: Agricultural Inputs
Bayer CropScience Limited engages in the manufacture, sale, and distribution of insecticides, fungicides, herbicides, and various other agrochemical products and corn seeds in India, Germany, Bangladesh, and internationally. It provides medicines primarily in the therapeutic areas of cardiology, gynecology, diabetes, oncology, and ophthalmology; and computed tomography, X-Ray, and magnetic resonance imaging devices. In addition, the company offers consumer health products that are used as a daily health solution to treat minor illnesses, as well as sells and distributes hybrid seeds, such as corn and paddy. Further, it provides digital farming products comprising FarmRise and other digital applications, such as drones for spray services, etc., as well as provides various technologies, such as remote sensing, IoT sensors, GPS, artificial intelligence, and data analytics to monitor and manage crop growth, soil quality, weather patterns, and other factors. The company also exports its products. Bayer CropScience Limited was founded in 1863 and is based in Thane, India.
Revenue projections:
Revenues for Bayer CropScience Limited are expected to drop compared to the previous year, which could be a cause for concern for investors. A decline in earnings may negatively impact the company's profitability, leading cautious investors to reconsider their positions, as it often signals challenges in overall financial health.
Financial Ratios:
| currentRatio | 1.916000 |
|---|---|
| forwardPE | 23.192244 |
| debtToEquity | 2.758000 |
| earningsGrowth | 0.131000 |
| revenueGrowth | 0.051000 |
| grossMargins | 0.404850 |
| operatingMargins | 0.150160 |
| trailingEps | 153.300000 |
| forwardEps | 192.555760 |
BAYERCROP's current ratio of 1.916 shows that the company has ample resources to service its short-term debt. This indicates a solid financial position, as BAYERCROP can rely on its cash reserves and current assets to cover its immediate liabilities without strain.
Bayer CropScience Limited's Forward PE is in a favorable range, meaning its stock price compares well with its earnings and isn't overpriced. This leaves room for growth, making it a compelling opportunity for investors looking to benefit from potential future gains.
BAYERCROP's forward EPS exceeding its trailing EPS implies that the company is projected to be more profitable this year. This suggests an improvement in financial performance, with analysts expecting BAYERCROP to generate stronger earnings compared to the previous financial year.
Price projections:
Over time, BAYERCROP's price projections have steadily declined, reflecting reduced confidence in the company's future performance. The downward revisions suggest analysts are becoming more conservative in their assessments.
Recommendation changes over time:
The analysts' recent buy bias for Bayer CropScience Limited indicates strong confidence in the stock's future performance. This could encourage more investors to view Bayer CropScience Limited as a worthwhile investment, positioning the company as a top choice for those seeking financial security and long-term growth opportunities.
If you have enjoyed reading, spread the word:
Good prospects:
Companies with the best and the worst fundamentals.
Latest Regulatory Filings for NSE500
Companies with the best and the worst technicals.
RAINMUMBAI Turns Rain Into a Financial Asset
India’s IT Sector Faces a Historic Breaking Point
How Independent Directors Failed Rs 2,500 Crore in Value